Generated Narrative: Citation 153881

url: Citation Delany-Moretlwe 2022 clinical trial

identifier: FEvIR Object Identifier/153881, https://pubmed.ncbi.nlm.nih.gov/35378077, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.26

version: 2.0.0-ballot

title: Delany-Moretlwe 2022 clinical trial

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2022-05-10

lastReviewDate: 2023-03-17

author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2022-02-27

statusDate

activity: PubMed Pubstatus of Revised

period: ?? --> 2022-03-12

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2022-03-14

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2022-04-05 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2022-05-11 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2022-04-04 20:10:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/35378077, https://www.ncbi.nlm.nih.gov/pmc//PMC9077443, https://doi.org/10.1016/S0140-6736(22)00538-4, pii/S0140-6736(22)00538-4

relatedIdentifier: https://clinicaltrials.gov/NCT03164564

Titles

-	Type	Language	Text
*	Primary title	English	Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.

Abstracts

-	Text	Copyright
*	BACKGROUND: Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and the fear of violence. Safe and effective long-acting agents for HIV prevention are needed for women. We aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women. METHODS: HPTN 084 was a phase 3, randomised, double-blind, double-dummy, active-controlled, superiority trial in 20 clinical research sites in seven countries in sub-Saharan Africa. Participants were eligible for enrolment if they were assigned female sex at birth, were aged 18-45 years, reported at least two episodes of vaginal intercourse in the previous 30 days, were at risk of HIV infection based on an HIV risk score, and agreed to use a long-acting reversible contraceptive method. Participants were randomly assigned (1:1) to either active cabotegravir with TDF-FTC placebo (cabotegravir group) or active TDF-FTC with cabotegravir placebo (TDF-FTC group). Study staff and participants were masked to study group allocation, with the exception of the site pharmacist who was responsible for study product preparation. Participants were prescribed 5 weeks of daily oral product followed by intramuscular injections every 8 weeks after an initial 4-week interval load, alongside daily oral pills. Participants who discontinued injections were offered open-label daily TDF-FTC for 48 weeks. The primary endpoints of the study were incident HIV infection in the intention-to-treat population, and clinical and laboratory events that were grade 2 or higher in all women who had received at least one dose of study product. This study is registered with ClinicalTrials.gov, NCT03164564. FINDINGS: From Nov 27, 2017, to Nov 4, 2020, we enrolled 3224 participants (1614 in the cabotegravir group and 1610 in the TDF-FTC group). Median age was 25 years (IQR 22-30); 1755 (54·7%) of 3209 had two or more partners in the preceding month. 40 incident infections were observed over 3898 person-years (HIV incidence 1·0% [95% CI 0·73-1·40]); four in the cabotegravir group (HIV incidence 0·2 cases per 100 person-years [0·06-0·52]) and 36 in the TDF-FTC group (1·85 cases per 100 person-years [1·3-2·57]; hazard ratio 0·12 [0·05-0·31]; p<0·0001; risk difference -1·6% [-1·0% to -2·3%]. In a random subset of 405 TDF-FTC participants, 812 (42·1%) of 1929 plasma samples had tenofovir concentrations consistent with daily use. Injection coverage was 93% of the total number of person-years. Adverse event rates were similar across both groups, apart from injection site reactions, which were more frequent in the cabotegravir group than in the TDF-FTC group (577 [38·0%] of 1519 vs 162 [10·7%] of 1516]) but did not result in injection discontinuation. Confirmed pregnancy incidence was 1·3 per 100 person-years (0·9-1·7); no congenital birth anomalies were reported. INTERPRETATION: Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women. FUNDING: National Institute of Allergy and Infectious Diseases, ViiV Healthcare, and the Bill & Melinda Gates Foundation. Additional support was provided through the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. ViiV Healthcare and Gilead Sciences provided pharmaceutical support.	Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

relatesTo

type: cites

citation:

UNAIDS Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. July 14, 2021. https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update-slideset

relatesTo

type: cites

citation:

WHO . World Health Organization; Geneva: 2015. Policy brief: pre-exposure prophylaxis (PrEP): WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)

relatesTo

type: cites

classifier: Journal Article

citation:

Celum CL, Delany-Moretlwe S, Baeten JM, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(suppl 4)

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/31328444/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/31328444

relatesTo

type: cites

classifier: Journal Article

citation:

Velloza J, Khoza N, Scorgie F, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32144874/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32144874

relatesTo

type: cites

classifier: Journal Article

citation:

Cottrell ML, Yang KH, Prince HM, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55–64.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26917574/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26917574

relatesTo

type: cites

classifier: Journal Article

citation:

Andrews CD, Yueh YL, Spreen WR, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25589630/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25589630

relatesTo

type: cites

classifier: Journal Article

citation:

Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25589631/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25589631

relatesTo

type: cites

classifier: Journal Article

citation:

Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331–e340.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/28546090/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/28546090

relatesTo

type: cites

classifier: Journal Article

citation:

Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/30408115/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/30408115

relatesTo

type: cites

classifier: Journal Article

citation:

Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595–608.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34379922/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34379922

relatesTo

type: cites

classifier: Journal Article

citation:

Balkus JE, Brown E, Palanee T, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2016;72:333–343.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26918545/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26918545

relatesTo

type: cites

classifier: Journal Article

citation:

Eshleman SH, Fogel JM, Piwowar-Manning E, et al. Characterization of HIV infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis (in press).

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35301540/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35301540

relatesTo

type: cites

classifier: Journal Article

citation:

Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384–390.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22935078/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22935078

relatesTo

type: cites

classifier: Journal Article

citation:

Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2017;62:e01710–e01717.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/29038282/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/29038282

relatesTo

type: cites

classifier: Journal Article

citation:

Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066) AIDS Res Hum Retroviruses. 2016;32:32–43.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26414912/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26414912

relatesTo

type: cites

classifier: Journal Article

citation:

Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–348.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24784763/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24784763

relatesTo

type: cites

classifier: Journal Article

citation:

Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224:1581–1592.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33740057/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33740057

relatesTo

type: cites

citation:

US Department of Health and Human Services Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. July, 2017. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf

relatesTo

type: cites

citation:

Emerson SS, Fleming TR. Parameter estimation following group sequential hypothesis testing. Biometrika. 1990;77:875–892.

relatesTo

type: cites

classifier: Journal Article

citation:

Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384:1003–1014.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33730454/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33730454

relatesTo

type: cites

classifier: Journal Article

citation:

Gray GE, Bekker LG, Laher F, et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N Engl J Med. 2021;384:1089–1100.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33761206/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33761206

relatesTo

type: cites

citation:

Palanee-Phillips T, Baeten J, Heller K, et al. HIV incidence remains high in women in South Africa: data from the ECHO trial. 10th International AIDS Society Conference on HIV Science; July 21–24, 2019 (abstr LBPEC23).

relatesTo

type: cites

classifier: Journal Article

citation:

Pillay D, Stankevitz K, Lanham M, et al. Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa. PLoS One. 2020;15

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32352969/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32352969

relatesTo

type: cites

classifier: Journal Article

citation:

Bärnighausen K, Geldsetzer P, Matse S, et al. Qualitative accounts of PrEP discontinuation from the general population in Eswatini. Cult Health Sex. 2021;23:1198–1214.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32633617/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32633617

relatesTo

type: cites

classifier: Journal Article

citation:

Quaife M, Eakle R, Cabrera Escobar MA, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38:120–133.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/28863752/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/28863752

relatesTo

type: cites

classifier: Journal Article

citation:

Minnis AM, Browne EN, Boeri M, et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80:394–403.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/30633040/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/30633040

relatesTo

type: cites

classifier: Journal Article

citation:

Laher F, Salami T, Hornschuh S, et al. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important. BMC Public Health. 2020;20

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33160341/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33160341

relatesTo

type: cites

classifier: Journal Article

citation:

Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25651245/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25651245

relatesTo

type: cites

classifier: Journal Article

citation:

Baeten JM, Brown ER, Hillier SL. Dapivirine vaginal ring for HIV-1 prevention. N Engl J Med. 2017;376:995–996.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/28273023/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/28273023

relatesTo

type: cites

classifier: Journal Article

citation:

Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803–815.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/31339677/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/31339677

relatesTo

type: cites

classifier: Journal Article

citation:

Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70:319–322.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/31125395/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/31125395

relatesTo

type: cites

citation:

Eshleman S, Fogel JM, Halvas EK, et al. CAB-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk. 29th Conference on Retroviruses and Opportunistic Infections; Feb 12–16, 2022 (abstr Oral-08).

relatesTo

type: comment-in

classifier: Comment

citation:

Lancet. 2022 May 7;399(10337):1754-1755

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35378079/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35378079

relatesTo

type: correction-in

classifier: Published Erratum

citation:

Lancet. 2022 May 7;399(10337):1778

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35526551/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35526551

relatesTo

type: comment-in

classifier: Comment

citation:

Nat Med. 2022 Aug;28(8):1542-1543

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35869309/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35869309

relatesTo

type: comment-in

classifier: Comment

citation:

Nature. 2022 Aug;608(7923):460-461

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35931763/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35931763

relatesTo

type: comment-in

classifier: Comment

citation:

Nature. 2022 Aug;608(7922):239

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35945377/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35945377

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1474-547X, ISOAbbreviation/Lancet, ISSN Linking/0140-6736, Medline Title Abbreviation/Lancet, NLM Unique ID/2985213R

title: Lancet (London, England)

publisherLocation: England

citedMedium: Internet

volume: 399

issue: 10337

articleDate: 2022-05-07

publicationDateText: 2022-May-07

language: English

pageString: 1779-1789

publicationForm

citedMedium: Internet without issue

articleDate: 2022-04-01

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/35378077/

webLocation

classifier: DOI Based

url: https://doi.org/10.1016/S0140-6736(22)00538-4

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Chemical

classifier: Anti-HIV Agents, Diketopiperazines, Pyridones, Emtricitabine, cabotegravir

classification

type: MeSH Heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication Type

classifier: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation Subset

classifier: IM

contributorship

complete: true

entry

contributor: Delany-Moretlwe S

forenameInitials: S

affiliation: Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: sdelany@wrhi.ac.za.

entry

contributor: Hughes JP

forenameInitials: JP

affiliation: Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

entry

contributor: Bock P

forenameInitials: P

affiliation: Desmond Tutu TB Centre, University of Stellenbosch, Stellenbosch, South Africa.

entry

contributor: Ouma SG

forenameInitials: SG

affiliation: Kisumu Clinical Research Site, Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.

entry

contributor: Hunidzarira P

forenameInitials: P

affiliation: Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.

entry

contributor: Kalonji D

forenameInitials: D

affiliation: HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.

entry

contributor: Kayange N

forenameInitials: N

affiliation: Blantyre Clinical Research Site, College of Medicine, University of Malawi, Blantyre, Malawi.

entry

contributor: Makhema J

forenameInitials: J

affiliation: Botswana Harvard AIDS Institute Partnership (BHP), Gaborone, Botswana.

entry

contributor: Mandima P

forenameInitials: P

affiliation: Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.

entry

contributor: Mathew C

forenameInitials: C

affiliation: Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.

entry

contributor: Spooner E

forenameInitials: E

affiliation: HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.

entry

contributor: Mpendo J

forenameInitials: J

affiliation: International AIDS Vaccine Initiative, Uganda Virus Research Institute, Entebbe, Uganda.

entry

contributor: Mukwekwerere P

forenameInitials: P

affiliation: Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.

entry

contributor: Mgodi N

forenameInitials: N

affiliation: Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.

entry

contributor: Ntege PN

forenameInitials: PN

affiliation: Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.

entry

contributor: Nair G

forenameInitials: G

affiliation: Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa.

entry

contributor: Nakabiito C

forenameInitials: C

affiliation: Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.

entry

contributor: Nuwagaba-Biribonwoha H

forenameInitials: H

affiliation: Eswatini Prevention Center, International Center for AIDS Care and Treatment Program at Columbia University Mailman School of Public Health, New York, NY, USA.

entry

contributor: Panchia R

forenameInitials: R

affiliation: Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

entry

contributor: Singh N

forenameInitials: N

affiliation: HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.

entry

contributor: Siziba B

forenameInitials: B

affiliation: Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.

entry

contributor: Farrior J

forenameInitials: J

affiliation: FHI 360, Durham, NC, USA.

entry

contributor: Rose S

forenameInitials: S

affiliation: FHI 360, Durham, NC, USA.

entry

contributor: Anderson PL

forenameInitials: PL

affiliation: Anschutz Medical Campus, University of Colorado, Aurora, CO, USA.

entry

contributor: Eshleman SH

forenameInitials: SH

affiliation: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

entry

contributor: Marzinke MA

forenameInitials: MA

affiliation: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

entry

contributor: Hendrix CW

forenameInitials: CW

affiliation: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

entry

contributor: Beigel-Orme S

forenameInitials: S

affiliation: Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

entry

contributor: Hosek S

forenameInitials: S

affiliation: Department of Psychiatry, Stroger Hospital of Cook County, Chicago, IL, USA.

entry

contributor: Tolley E

forenameInitials: E

affiliation: FHI 360, Durham, NC, USA.

entry

contributor: Sista N

forenameInitials: N

affiliation: FHI 360, Durham, NC, USA.

entry

contributor: Adeyeye A

forenameInitials: A

affiliation: Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.

entry

contributor: Rooney JF

forenameInitials: JF

affiliation: Gilead Sciences, Foster City, CA, USA.

entry

contributor: Rinehart A

forenameInitials: A

affiliation: ViiV Healthcare, Durham, NC, USA.

entry

contributor: Spreen WR

forenameInitials: WR

affiliation: ViiV Healthcare, Durham, NC, USA.

entry

contributor: Smith K

forenameInitials: K

affiliation: ViiV Healthcare, Durham, NC, USA.

entry

contributor: Hanscom B

forenameInitials: B

affiliation: Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

entry

contributor: Cohen MS

forenameInitials: MS

affiliation: University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.

entry

contributor: Hosseinipour MC

forenameInitials: MC

affiliation: University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; UNC Project-Malawi, Lilongwe, Malawi.

entry

contributor: HPTN 084 study group

Generated Narrative: Practitioner #author0

name: Sinead Delany-Moretlwe

Generated Narrative: Practitioner #author1

name: James P Hughes

Generated Narrative: Practitioner #author2

name: Peter Bock

Generated Narrative: Practitioner #author3

name: Samuel Gurrion Ouma

Generated Narrative: Practitioner #author4

name: Portia Hunidzarira

Generated Narrative: Practitioner #author5

name: Dishiki Kalonji

Generated Narrative: Practitioner #author6

name: Noel Kayange

Generated Narrative: Practitioner #author7

name: Joseph Makhema

Generated Narrative: Practitioner #author8

name: Patricia Mandima

Generated Narrative: Practitioner #author9

name: Carrie Mathew

Generated Narrative: Practitioner #author10

name: Elizabeth Spooner

Generated Narrative: Practitioner #author11

name: Juliet Mpendo

Generated Narrative: Practitioner #author12

name: Pamela Mukwekwerere

Generated Narrative: Practitioner #author13

name: Nyaradzo Mgodi

Generated Narrative: Practitioner #author14

name: Patricia Nahirya Ntege

Generated Narrative: Practitioner #author15

name: Gonasagrie Nair

Generated Narrative: Practitioner #author16

name: Clemensia Nakabiito

Generated Narrative: Practitioner #author17

name: Harriet Nuwagaba-Biribonwoha

Generated Narrative: Practitioner #author18

name: Ravindre Panchia

Generated Narrative: Practitioner #author19

name: Nishanta Singh

Generated Narrative: Practitioner #author20

name: Bekezela Siziba

Generated Narrative: Practitioner #author21

name: Jennifer Farrior

Generated Narrative: Practitioner #author22

name: Scott Rose

Generated Narrative: Practitioner #author23

name: Peter L Anderson

Generated Narrative: Practitioner #author24

name: Susan H Eshleman

Generated Narrative: Practitioner #author25

name: Mark A Marzinke

Generated Narrative: Practitioner #author26

name: Craig W Hendrix

Generated Narrative: Practitioner #author27

name: Stephanie Beigel-Orme

Generated Narrative: Practitioner #author28

name: Sybil Hosek

Generated Narrative: Practitioner #author29

name: Elizabeth Tolley

Generated Narrative: Practitioner #author30

name: Nirupama Sista

Generated Narrative: Practitioner #author31

name: Adeola Adeyeye

Generated Narrative: Practitioner #author32

name: James F Rooney

Generated Narrative: Practitioner #author33

name: Alex Rinehart

Generated Narrative: Practitioner #author34

name: William R Spreen

Generated Narrative: Practitioner #author35

name: Kimberly Smith

Generated Narrative: Practitioner #author36

name: Brett Hanscom

Generated Narrative: Practitioner #author37

name: Myron S Cohen

Generated Narrative: Practitioner #author38

name: Mina C Hosseinipour

Generated Narrative: Organization #author39

name: HPTN 084 study group

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation Delany-Moretlwe 2022 clinical trial

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Adult

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Anti-HIV Agents

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Child

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Diketopiperazines

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Emtricitabine

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Female

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: HIV Infections

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: chemically induced

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: epidemiology

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: prevention & control

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: HIV Seropositivity

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: HIV-1

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Infant, Newborn

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Pregnancy

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Pyridones

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No